If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
=== Synergism === Several antibiotics have been tested as partner drugs of oritavancin. Among these "companions" drugs, fosfomycin displayed (in vitro and in vivo) synergistic activity when administered together with oritavancin against VRE strains (both vanA and vanB), including biofilm-producing isolates. This synergistic action has also been proposed for the prevention of vascular graft infections by impregnating prostheses with a combination of oritavancin and fosfomycin.
Open-source artificial intelligence, as defined by the Open Source Initiative, is an AI system that is freely available to use, study, modify, and share. This includes datasets used to train the model, its code, and its model parameters, promoting a collaborative and transparent approach to AI development so someone could create a substantially similar result. The debate over what should count as 'open-source' given a range of openness among AI projects has been significant. Some large language models touted as open-sourced that are merely open weights and do not release training data and code have been criticized as "openwashing" systems that are mostly closed. For example, Artificial Analysis gives an "Openness Index" of 83% to Nvidia's Nemotron family, for its greater transparency in methodology, pre-training data, and post-training data, while China's frontier open weights models broadly score under 50%. Open-source AI is a major issue in geopolitics and artificial intelligence controversies, sometimes characterized as an AI arms race or AI Cold War between the US and China. Broadly, models released by Chinese companies, such as DeepSeek, Alibaba Cloud, Moonshot AI and Z.ai, use an open weights framework, under more permissive software licenses like Apache or MIT. United States AI companies, including OpenAI, Anthropic, SpaceXAI, Google DeepMind largely favor a proprietary software framework, especially for larger models. These are in part national government policy decisions, because public access to AI technology has many consequences.
Methyl sulfides methylmercaptan/methanethiol (MM) dimethyl sulfide (DMS) dimethyl disulfide (DMDS) dimethyl trisulfide (DMTS) Benzopyrrole volatiles indole skatole Hydrogen sulfide (H2S) (H2S) is the most common volatile sulfur compound in feces. The odor of feces may be increased when various pathologies are present, including:
The second modification required is the addition of an azide to the N-terminus. Unlike the addition of the alkyne this can be done on the whole peptide, or solely on the N-terminal residue which is added to the rest of the oligopeptide by solid-phase peptide synthesis. The addition of the azide occurs by Cu(II)-catalyzed diazo transfer.
==== Temgicoluril ==== Temgicoluril (Mebicar) is an anxiolytic produced in Latvia and used in Eastern Europe. Temgicoluril has an effect on the structure of limbic-reticular activity, particularly on the hypothalamus, as well as on all four basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Temgicoluril decreases noradrenaline, increases serotonin, and exerts no effect on dopamine.
Sources: en.wikipedia.org
Cardiovascular: low blood pressure, high blood pressure, swelling Central nervous system: insomnia Dermatological: rash Gastrointestinal: diarrhea, abdominal pain Hematological: eosinophilia Respiratory: dyspnea Other: injection site reactions, fever, hypersensitivity Less common, but serious adverse events reported in the literature include
== History == The modern understanding of the pathway of glycolysis took almost 100 years to fully learn. The combined results of many smaller experiments were required to understand the entire pathway. The first steps in understanding glycolysis began in the 19th century. For economic reasons, the French wine industry sought to investigate why wine sometimes turned distasteful, instead of fermenting into alcohol. The French scientist Louis Pasteur researched this issue during the 1850s. His experiments showed that alcohol fermentation occurs by the action of living microorganisms, yeasts, and that glucose consumption decreased under aerobic conditions (the Pasteur effect).
=== Cost === The recognised metalloids and their closer neighbours mostly cost less than silver; only polonium and astatine are more expensive than gold, on account of their significant radioactivity. As of 5 April 2014, prices for small samples (up to 100 g) of silicon, antimony and tellurium, and graphite, aluminium and selenium, average around one third the cost of silver (US$1.5 per gram or about $45 an ounce). Boron, germanium, and arsenic samples average about three-and-a-half times the cost of silver. Polonium is available for about $100 per microgram. Zalutsky and Pruszynski estimate a similar cost for producing astatine. Prices for the applicable elements traded as commodities tend to range from two to three times cheaper than the sample price (Ge), to nearly three thousand times cheaper (As).
=== Present day === Modern embalming is most often performed to ensure a better presentation of the deceased for viewing by friends and relatives. It is also used for medical research or training, transportation of deceased, especially across national borders, and in many instances for above ground burial in a vault or mausoleum. A successful viewing of the body is considered to be helpful in the grieving process. Embalming has the potential to prevent mourners from having to deal with the decomposition and eventual putrescence of the body. Despite a common misconception, embalming is not mandatory in the United States, although it is a general legal requirement for international repatriation of human remains to the U.S. (exceptions do occur). There are no universal international preservation requirements for repatriation of human remains, but requirements for embalming do exist for a variety of countries depending on locality and circumstance. Some international standards do exist however, such as the Strasbourg Agreement of the Council of Europe, agreed to by more than 20 States in Europe, which only requires embalming in cases where the individual died due to an infectious disease.
In 1769, William Cullen called attention to diabetic urine that was "insipid" in taste:I myself, indeed, think I have met with one instance of diabetes in which the urine was perfectly insipid; and it would seem that a like observation had occurred to Dr. Martin Lister. I am persuaded, however, that such instances are very rare; and that the other is much more common and perhaps the almost universal occurrence. I judge therefore, that the presence of such a saccharine matter may be considered as the principal circumstance in idiopathic diabetes.In 1788, Thomas Cawley published a case study in the London Medical Journal based on an autopsy of a diabetic patient. He suggested a link between the pancreas and diabetes after observing stones and signs of tissue damage in the patient's pancreas. The significance of this discovery went unappreciated for another hundred years. In 1794, Johann Peter Frank of the University of Pavia found that his patients were characterized by "long continued abnormally increased secretion of non-saccharine urine which is not caused by a diseased condition of the kidneys". He introduced the term insipidus, derived from the Latin ('tasteless'). Frank is often credited as the first physician to describe clinical differences between diabetes mellitus and diabetes insipidus. This claim, however, warrants further examination given prior instances of comparable description (e.g. those by William Cullen). It has been noted that 1792 seems to be the year when "unequivocal" diabetes insipidus was first described in the medical literature.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.